Page 1

inventiva PRESS RELEASE Inventiva reports 2021 Third Quarter Financial Information¹ Cash and cash equivalents at € 105.7m as of September 30 , 2021 Revenues of € 0.2m for the first nine months of 2021 - Daix ( France ) , Long Island City ( New York , United States ) , November 10 , 2021 – Inventiva ( Euronext Paris and Nasdaq : IVA ) , a clinical - stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non - alcoholic steatohepatitis ( NASH ) , mucopolysaccharidoses ( MPS ) and other diseases with significant unmet medical needs , today reported its cash position as of September 30 , 2021 and its revenues for the first nine months of 2021 . Cash Position As of September 30 , 2021 , Inventiva's cash and cash equivalents stood at € 105.7 million , compared to € 93.6 million as of June 30 , 2021 and € 105.72 million as of December 31 , 2020 . Net cash used in operating activities amounted to € 31.6 million for the first nine months of 2021 compared to ( € 19.4 ) million for the same period in 2020. R & D expenses for the first nine months of 2021 were up by 88 % compared to the same period in 2020 , mainly driven by the costs associated with the preparation and initiation of the NATIV3 Phase III clinical trial with lanifibranor in NASH , and to a lesser extent , by the increase of general and administrative expenses ( G & A ) expenses ( + 51 % ) resulting from Inventiva's dual listing status . Net cash generated from financing activities for the first nine months of 2021 amounted to € 23.9 million , mainly due to the sale of $ 30 million in gross proceeds of the Company's ordinary shares in the form American Depositary Shares ( " ADS " ) on September 23 , 2021. The sale was made through the Company's At - The - Market ( ATM ) program established on August 2 , 2021 , to existing and new specialized institutional investors . For the same period in 2020 , net cash generated from financing activities amounted to € 111.6 million , driven by : the issuance of € 15 million ( gross proceeds ) of ordinary shares to certain existing investors in the Company , the entry into € 10 million in French state - guaranteed credit agreements with a syndicate of French banks , and the receipt of € 94.9 million³ ( gross proceeds ) following the successful IPO on the Nasdaq Global Market in July 2020 . Over the third quarter of 2021 , the Company recorded a positive exchange rate effect on cash and cash equivalents of € 3.0 million . Considering its current R & D and clinical development programs and excluding additional financial resources that may originate from funding activities , Inventiva's cash runway will allow the Company to fund its operations through the first quarter of 2023 . Revenues The Company's revenues for the first nine months of 2021 amounted to € 0.2 million , as compared to € 0.3 million for the same period in 2020. As part of its collaboration with AbbVie in auto - immune diseases , Inventiva is eligible to receive development , regulatory and commercial milestone payments as well as royalty payments . As such , 1 Non - audited financial information . 2 The cash position as of December 31 , 2020 amounted to € 113.7 million as published in the press releases on March 4 , 2021 , May 12 , 2021 and July 28 , 2021 and included cash and cash equivalents as well as short - term deposits which were included in the category " other current assets " in the IFRS statement of financial position . 3 Based on an exchange rate of $ 1.1342 per euro , the exchange rate published by the European Central Bank on July 9 , 2020 . 1